Elevated Serum Concentrations of Interleukin‐10 in Nonneutropenic Patients with Invasive Aspergillosis

tent aliquots are used, 1 nonresponder would be expected only among 10 million OPV recipients. To conclude, stabilized OPV will boost global plans to eradicate poliomyelitis by 2005 [8]. Multiple doses of potent OPV will be an asset to disease surveillance and will stop wild-virus transmission in Angola and elsewhere. Stabilized formulations will enhance the probability of every OPV recipient receiving the full immunizing dose. Field scrutiny of OPV, existing or stabilized, for 3 serotypes should banish poliomyelitis among recipients of multiple doses of OPV.